Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAsset Writedowns and ImpairmentBeginning Cash BalanceCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aytu Biopharma (AYTU) Beginning Cash Balance: 2009-2025

Historic Beginning Cash Balance for Aytu Biopharma (AYTU) over the last 17 years, with Sep 2025 value amounting to $31.0 million.

  • Aytu Biopharma's Beginning Cash Balance rose 54.71% to $31.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $20.1 million, marking a year-over-year increase of 0.72%. This contributed to the annual value of $20.0 million for FY2025, which is 12.96% down from last year.
  • Latest data reveals that Aytu Biopharma reported Beginning Cash Balance of $31.0 million as of Q3 2025, which was up 70.32% from $18.2 million recorded in Q2 2025.
  • Over the past 5 years, Aytu Biopharma's Beginning Cash Balance peaked at $62.0 million during Q1 2021, and registered a low of $18.2 million during Q2 2025.
  • In the last 3 years, Aytu Biopharma's Beginning Cash Balance had a median value of $20.0 million in 2023 and averaged $21.0 million.
  • Its Beginning Cash Balance has fluctuated over the past 5 years, first skyrocketed by 208.82% in 2021, then tumbled by 61.01% in 2022.
  • Aytu Biopharma's Beginning Cash Balance (Quarterly) stood at $40.6 million in 2021, then crashed by 41.29% to $23.8 million in 2022, then declined by 16.16% to $20.0 million in 2023, then rose by 0.72% to $20.1 million in 2024, then soared by 54.71% to $31.0 million in 2025.
  • Its last three reported values are $31.0 million in Q3 2025, $18.2 million for Q2 2025, and $20.4 million during Q1 2025.